Alejandra Bravo-Molina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alejandra Bravo-Molina has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Jose Patricio Linares-Palomino
University Hospital Virgen de las Nieves, Department of Vascular Surgery, Granada, Spain
4 shared publications - Silvia Lozano-Alonso
Departamento de Cirugía Vascular, Hospital Universitario San Cecilio de Granada, Granada, Spain
4 shared publications Blanca Vera-Arroyo
Unidad de Angiología y Cirugía Vascular, Hospital Universitario Virgen de la Victoria, Málaga, Spain
2 shared publicationsEduardo Ros-Díe
Unidad de Angiología y Cirugía Vascular, Complejo Hospitalario Universitario de Granada, Granada, Spain
2 shared publicationsJosé Hernández-Quero
Infectious DIseases Unit, San Cecilio University Hospital, Granada, Spain
2 shared publicationsLuis Miguel Salmerón-Febres
Unidad de Angiología y Cirugía Vascular, Complejo Hospitalario Universitario de Granada, Granada, Spain
2 shared publications
Latest Publications
- 1 February 2018
- Published by Elsevier in Foot and Ankle Surgery
- Vol. 24 (1) , 60-64
Inter-observer agreement of the Wagner, University of Texas and PEDIS classification systems for the diabetic foot syndrome
- 1 February 2018
- Published by Elsevier in Foot and Ankle Surgery
- Vol. 24 (1) , 60-64
Inter-observer agreement of the Wagner, University of Texas and PEDIS classification systems for the diabetic foot syndrome
- 1 March 2016
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 30 (2) , 329-334
Influence of wound scores and microbiology on the outcome of the diabetic foot syndrome
- 1 March 2016
- Published by Elsevier in Journal of Diabetes and its Complications
- Vol. 30 (2) , 329-334
Influence of wound scores and microbiology on the outcome of the diabetic foot syndrome
- 21 November 2014
- Published by Real Academia de Medicina y Cirugia de Andalucia Oriental in ACTUALIDAD MEDICA
- Vol. 99 (793) , 19-21
Treatment of two cases of oral cavity venous malformation with sclerotherapy
- 21 November 2014
- Published by Real Academia de Medicina y Cirugia de Andalucia Oriental in ACTUALIDAD MEDICA
- Vol. 99 (793) , 19-21
Treatment of two cases of oral cavity venous malformation with sclerotherapy
- 15 August 2013
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 27 (8) , 1162-1168
Clinical and Health Costs Impact of Progress in Diagnosis and Treatment in Venous Thromboembolic Disease: Evolution in 15 Years
- 15 August 2013
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 27 (8) , 1162-1168
Clinical and Health Costs Impact of Progress in Diagnosis and Treatment in Venous Thromboembolic Disease: Evolution in 15 Years
- 1 May 2013
- Published by ARAN Ediciones in Angiologia
- Vol. 65, 52-54
Trombosis popliteodistal en mujer joven con lupus eritematoso sistémico y síndrome antifosfolípido
- 1 May 2013
- Published by ARAN Ediciones in Angiologia
- Vol. 65, 52-54
Trombosis popliteodistal en mujer joven con lupus eritematoso sistémico y síndrome antifosfolípido
- 1 May 2013
- Published by ARAN Ediciones in Angiologia
- Vol. 65, 22-23
Aneurisma de aorta abdominal trombosado
- 1 May 2013
- Published by ARAN Ediciones in Angiologia
- Vol. 65, 22-23
Aneurisma de aorta abdominal trombosado
- Open Access
- 13 July 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (11) , 2682-2685
Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm
The aim of the study was to assess the in vitro activity of linezolid and daptomycin, alone and in combination, against three Staphylococcus aureus isolates using a pharmacokinetic/pharmacodynamic (PK/PD) model of biofilm for 3 days. One non-clinical methicillin-resistant S. aureus isolate (N315) and two clinical methicillin-resistant S. aureus isolates were evaluated. Simulated regimens included high-dose daptomycin (10 mg/kg once daily) and linezolid (600 mg twice daily), alone and in combination. Against all three strains, neither linezolid nor daptomycin alone was bactericidal against biofilm-embedded bacteria (BB). Against planktonic bacteria (PB) only daptomycin was bactericidal. In contrast, the combination of linezolid and daptomycin demonstrated greater activity than either of the two agents alone, being bactericidal against both PB and BB, almost reaching the limit of detection at 72 h. In this in vitro PK/PD model of mature biofilms, a combination of linezolid plus daptomycin was more effective than each agent alone, representing another potential option to treat S. aureus biofilm-associated infections.
- 13 July 2012
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 67 (11) , 2682-2685
Open AccessActivity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm
The aim of the study was to assess the in vitro activity of linezolid and daptomycin, alone and in combination, against three Staphylococcus aureus isolates using a pharmacokinetic/pharmacodynamic (PK/PD) model of biofilm for 3 days. One non-clinical methicillin-resistant S. aureus isolate (N315) and two clinical methicillin-resistant S. aureus isolates were evaluated. Simulated regimens included high-dose daptomycin (10 mg/kg once daily) and linezolid (600 mg twice daily), alone and in combination. Against all three strains, neither linezolid nor daptomycin alone was bactericidal against biofilm-embedded bacteria (BB). Against planktonic bacteria (PB) only daptomycin was bactericidal. In contrast, the combination of linezolid and daptomycin demonstrated greater activity than either of the two agents alone, being bactericidal against both PB and BB, almost reaching the limit of detection at 72 h. In this in vitro PK/PD model of mature biofilms, a combination of linezolid plus daptomycin was more effective than each agent alone, representing another potential option to treat S. aureus biofilm-associated infections.